Corbus Pharmaceuticals (CRBP) Competitors

Corbus Pharmaceuticals logo
$2.06 -0.37 (-15.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 -0.01 (-0.49%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRBP vs. AUTL, AGEN, OCGN, XFOR, and KYTX

Should you buy Corbus Pharmaceuticals stock or one of its competitors? Corbus Pharmaceuticals's main competitors and comparable companies include Autolus Therapeutics (AUTL), Agenus (AGEN), Ocugen (OCGN), X4 Pharmaceuticals (XFOR), and Kyverna Therapeutics (KYTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corbus Pharmaceuticals compare to Autolus Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Corbus Pharmaceuticals has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A
Autolus Therapeutics$75.39M3.25-$287.53M-$0.97N/A

Corbus Pharmaceuticals presently has a consensus target price of $35.67, suggesting a potential upside of 1,562.78%. Autolus Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 986.96%. Given Corbus Pharmaceuticals' higher probable upside, equities analysts clearly believe Corbus Pharmaceuticals is more favorable than Autolus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88

Corbus Pharmaceuticals has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -186.37%. Corbus Pharmaceuticals' return on equity of -100.96% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus PharmaceuticalsN/A -100.96% -82.70%
Autolus Therapeutics -186.37%-263.25%-48.04%

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 1.09 beat Corbus Pharmaceuticals' score of -0.01 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corbus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Autolus Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corbus Pharmaceuticals has a beta of 2.8, indicating that its share price is 180% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals and Autolus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Agenus?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Corbus Pharmaceuticals has a beta of 2.8, meaning that its share price is 180% more volatile than the broader market. Comparatively, Agenus has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Corbus Pharmaceuticals currently has a consensus target price of $35.67, suggesting a potential upside of 1,562.78%. Agenus has a consensus target price of $25.00, suggesting a potential upside of 318.41%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Agenus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Corbus Pharmaceuticals had 6 more articles in the media than Agenus. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 0 mentions for Agenus. Agenus' average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.01 indicating that Agenus is being referred to more favorably in the news media.

Company Overall Sentiment
Corbus Pharmaceuticals Neutral
Agenus Neutral

Agenus has a net margin of 22.10% compared to Corbus Pharmaceuticals' net margin of 0.00%. Agenus' return on equity of -27.16% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus PharmaceuticalsN/A -100.96% -82.70%
Agenus 22.10%-27.16%26.91%

Agenus has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A
Agenus$114.20M2.37$120K$0.669.05

Summary

Agenus beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Ocugen has higher revenue and earnings than Corbus Pharmaceuticals. Ocugen is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocugen$4.41M59.71-$67.85M-$0.20N/A
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 1,124.23%. Corbus Pharmaceuticals has a consensus target price of $35.67, indicating a potential upside of 1,562.78%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Ocugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than Ocugen. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.04 beat Corbus Pharmaceuticals' score of -0.01 indicating that Ocugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocugen
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corbus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Ocugen has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.8, suggesting that its stock price is 180% more volatile than the broader market.

Corbus Pharmaceuticals' return on equity of -100.96% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
OcugenN/A -127,987.80% -98.50%
Corbus Pharmaceuticals N/A -100.96%-82.70%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Ocugen on 9 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

X4 Pharmaceuticals has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the broader market.

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.05 beat Corbus Pharmaceuticals' score of -0.01 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
X4 Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corbus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Corbus Pharmaceuticals has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
X4 Pharmaceuticals$35.11M8.39-$79.20M-$0.67N/A
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A

Corbus Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -474.74%. X4 Pharmaceuticals' return on equity of -49.62% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
X4 Pharmaceuticals-474.74% -49.62% -30.80%
Corbus Pharmaceuticals N/A -100.96%-82.70%

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

X4 Pharmaceuticals currently has a consensus target price of $11.25, suggesting a potential upside of 278.79%. Corbus Pharmaceuticals has a consensus target price of $35.67, suggesting a potential upside of 1,562.78%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than X4 Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
X4 Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Corbus Pharmaceuticals beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Kyverna Therapeutics' return on equity of -86.87% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -86.87% -65.74%
Corbus Pharmaceuticals N/A -100.96%-82.70%

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 5 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.43 beat Corbus Pharmaceuticals' score of -0.01 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Corbus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Kyverna Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 586.55%. Corbus Pharmaceuticals has a consensus target price of $35.67, indicating a potential upside of 1,562.78%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Kyverna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna TherapeuticsN/AN/A-$161.31M-$2.77N/A
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A

Kyverna Therapeutics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.8, meaning that its stock price is 180% more volatile than the broader market.

Summary

Kyverna Therapeutics and Corbus Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRBP vs. The Competition

MetricCorbus PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$42.46M$3.92B$7.41B$10.84B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-0.3423.5032.4728.82
Price / SalesN/A15.618.075.38
Price / CashN/A22.6520.7221.66
Price / Book0.504.124.313.50
Net Income-$78.54M-$24.03M$3.50B$394.12M
7 Day Performance-39.23%-9.59%-7.90%-8.90%
1 Month Performance-53.39%-13.66%-10.43%-12.00%
1 Year Performance-82.38%-8.02%-3.39%-9.59%

Corbus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRBP
Corbus Pharmaceuticals
3.3692 of 5 stars
$2.06
-15.2%
$35.67
+1,631.4%
-79.5%$42.46MN/AN/A36
AUTL
Autolus Therapeutics
3.6853 of 5 stars
$1.19
-3.6%
$10.00
+740.3%
-22.9%$328.93M$75.39MN/A752
AGEN
Agenus
2.0375 of 5 stars
$6.87
-4.8%
$25.00
+263.9%
+46.2%$326.68M$114.20M10.4181
OCGN
Ocugen
1.6222 of 5 stars
$0.87
-9.0%
$9.50
+987.5%
-35.7%$325.87M$4.41MN/A116
XFOR
X4 Pharmaceuticals
1.8352 of 5 stars
$3.17
-1.9%
$11.25
+254.9%
-18.9%$320.24M$35.11MN/A45

Related Companies and Tools


This page (NASDAQ:CRBP) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners